electroCore Q2 2026 revenue $9.5M (+28% YoY); net loss narrows to $3.1M; raises FY 2026 guidance to >30% growth

electroCore, Inc.

Q2 net sales $9.5M, up 28% YoY from $7.4M; GAAP net loss $3.1M ($0.33/share) vs $3.7M ($0.44) prior year.
Adjusted EBITDA net loss improved 26% to $1.8M from $2.4M.
Quell product line sales $1.3M, up ~700% YoY; Truvaga revenue $1.3M, up 27% YoY.
VA channel: Rx gammaCore revenue up 11% YoY; ~16,400 VA patients (2.7% penetration of addressable headache market).
Company raises FY 2026 revenue guidance to >30% year-over-year growth; targets positive Adjusted EBITDA in Q3 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.